"Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors With Human Immunodeficiency Virus" currently #18 of 39 trials at clinicaltrialsdotcom. Posted 4/1/13.
I'm not sure which is the more bullish indication...the ongoing clinical mojo...
...or the Message Board lunacy that seems to accompany the clinical momentum.
At times it almost seems like a race.
Highest marks for your creative writing skills, bilkboy...
Yer gonna sit here all month long and copy & paste your prior posts...
Brilliant...but unwise. Yer boss is gonna replace you with a machine.
Best get busy...dazzle us.
No doubt about it, Chris has a great sense of humor.
With his references to scan evidence of tumor necrosis, I can't help but wonder what dose they are working..and if they've made any attempt as yet to mitigate side effects with dose reduction. Poor guy sounds in desperate need of a drug holiday...
Sometimes the only sure fix for the "voices in the head" syndrome...
...is a little double ott buckshot 12 gauge remediation.
"So, other than saving us from ourselves, what's your point?"
JMHO - but this milkman guy has got to be some sort of paid cubicle monkey with an agenda.
According to Yahoo, the milkman, neverlosenyc, and myturdsarestinky69 user accounts were all created on the same day - 3/11/13. They appeared out of nowhere, with no prior posts anywhere, playing it up as EXEL bulls...publishing a bunch of distractive crapola and accusing everyone of having aliases. It's pretty darned apparent that these 3 are all the same distractive source.
Of the three, the milkman has chosen to hang out here...evolving by the moment into an ever-increasing target for the ignore button.
The Milkman on EXEL:
3/11 - "I can't think of a better stock to own right now. You and the others are very intelligent to be holding, that much is clear after reading all your other messages. No way this goes lower. Impossible."
3/13 - "EXEL is very undervalued here at $4.75. Good blocks bought at ask on L3."
3/14 - "It is so undervalued it gets my (me?) somewhat giddy..."
3/15 - "Adding much more here at $4.63..."
3/27 - "Biotech is all about the science and the people running the company. Charts don't matter. EXEL has a drug that has an "unexplained" bone met thing. That's it for now."
Clueless blather...Can't we find this guy a job in politics? Maybe mayor of Winnemucca?
nomad_celsius12 apologized and vanished from this MB on 3/18...one week after these 3 stooges showed up. I wonder now if he was apologizing for indiscretions past or future...cuz in my humble opinion, his misguided persona has split into these three muskateers that has somehow recoalesced into this milkman moron. I think it's time to vote him off the island.
Just a heads up...
At least 3 mBC presentations from the NCCN annual meeting have shown up as a CME slideset available at clinicalcareoptionsdotcom. This slide show is formatted from a 3/14/13 NCCN conference presentation titled "New Developments in Metastatic Breast Cancer" - a three part series sponsored by the NCCN, CCO, and Genentech. I think this is a positive indication that more of those NCCN abstracts will be become available, and hopefuly we'll get some insights as to what data was actually presented by EXEL.
"Gotta say there Milkman, you sound an awful lot like a guy who signed off just about the time you showed up."
Ernie, you most certainly mean that same feller that found Jesus and posted a universal apology to the entire EXEL message board...right after he publicly shorted EXEL at $4.36.
One thing I learned long ago about those heartfelt apologies...
Ya gotta consider the source...
Joe - This is some pretty cool beans...
Your conceptualization of resetting to normalized "bonespeak" is interesting.
"Inhibiting vascular growth may counter signals from metastatic cancer cells to grow new blood vessels thereby resetting "normal" communication/signaling between osteoblasts/clasts and other stromal bone cells. The effects on osteoblasts/clasts may be indirect and mediated by disrupting signaling between cancer and endothelial cells."
To my knowledge, the most durable of all the bone responses has been the RCC patient that at poster time had been pain-free for 73 weeks and counting.
Assuming this "normalization" has also resulted in a similarly durable bone scan, that fortunate patient must have realized quite a fan-following amongst research clinicians. These next few rounds of data release should provide some entertainment.
I've been looking for a specific Exelixis statement of biologic rationale that may have driven the MM trial. This BusinessWire posting from 7/26/12 was about all I could find...
"Massachusetts General Hospital (MGH), is conducting a pilot phase 1 clinical trial of cabozantinib in patients with relapsed or refractory multiple myeloma, a disease for which there is evidence of MET's role in pathogenesis. "
"The phase 1 multiple myeloma trial is designed to assess the safety, tolerability, and preliminary activity of cabozantinib in patients with relapsed or refractory myeloma with bone disease. The first cohort of patients will receive 40 mg of cabozantinib daily...."
The remainder wouldn't copy, but the article goes on to simply suggest that subsequent cohorts would dose to either 20mg or 60mg...dependent upon bone scan response at 12 weeks. Truthfully, I was happy to find an MET-driven rationale for the trial...and not disturbed by the lack of data thus far. They may not have found the response they were looking for at 40mg. All the dosing data to date suggests diminishing efficacy +/- 40mg.
JMHO - but I'da hunted that dog a bit harder...
All of the literature I have read portends that bone metastases in Multiple Myeloma are entirely osteolytc. Is it likely that we can extend the rationale of your observations in RCC and extrapolate bone scan response for the MM trial? Is there some other mechanism at play...or could this be an apples-to-apples comparison?
I guess what I'm asking is: Are all osteolytic lesions equal?
Or do they differentiate by the nature of their origination?
Thanks in advance...
For those of you with whom I've shared correspondence, you know that I most often post with an easily acknowledged web reference. If I post an opinion that is solely of my own concoction, I normally indicate that the opinion is my own. If I have intentionally misled any member of this message board to any end - other than a favorable posture toward the clinical future of cabozantinib - please accept my apologies. I seldom - if ever - converse on EXEL's finances. Don't understand 'em. Don't want to... Don't need to...
I'm onboard as a fan of the science...just as I was fan of the sciences developed by HGSI and INHX prior to their IP sellout to big pharma. Admittedly, it's the only reason I'm here...
I have no aliases on this message board, nor any other. That would be pointless.
Your slovenly commentary has supplemented my earlier analysis.
Your condition is clinically recognized as inter-vertebral-cranio-penial decay.
Your deteriorating future is spineless, brainless, and testicularly featureless.
I read a pretty fair tarot card too, but I'll hafta charge you for that.
Call me anytime at 1-800-IMADUMMY2
$30 a minute on a 30-year astrologic cure cycle oughta do the trick.
Your credit's good w/ me you sick puppy...
But I'll need a $100K down to cover expenses...
Just make that check out to Exelixis, Inc...
Man...yer sure gettin' warm now...
You showed up here a few weeks ago, trying to portray a credible investor/ poster You failed.
Today...yer a lunatic. Someone should conduct a trial study that identifies your craniopenial decay.
That's when the string breaks that connect yer balls to yer brain....
...and leaves you an intellectual eunuch.
Wamme to clue you in as to what a eunuch is...??
" I have been told many employees fled the co. because of MM."
"I know a guy whose PSA dropped just w/ cabozantinib therapy alone..."
Just how many dimwitted lies you got in yer bag o' tricks?
Wamme to call you out each time you lie ?
Bend over and crack that vertical smile for your boiler-room boss, cubicle boy...
It's the only meat yer gonna find...